favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib
MK-3475-495
Phase 2 small_molecule active
Quick answer
favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib for Stage IV non-small cell lung cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Stage IV non-small cell lung cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active